Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIT225 add-on study in HIV-1 patients with partial immune reconstitution on suppressive cART
ACTRN12621001354875Phase 2Completed
- Sponsor
- Biotron Ltd
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BIT225 in Human immunodeficiency virus infection type 1, sponsored by Biotron Ltd. Primary endpoints: Change in immune, immune activation, inflammation and viral markers and Safety and tolerability of BIT225. Started Jan 2022; status: completed.
02
Drugs
BIT225
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ACTRN12621001354875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001354875.